INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 29 February 2016
|
Net Assets |
£189m |
|
Net Assets per share |
483p |
|
Share price |
425p |
|
Total value of unquoted investments |
£22m |
|
Total number of portfolio companies |
80 |
Top Ten Holdings
|
Company Name |
% NAV |
|
Celgene |
9.2 |
|
Amgen |
8.3 |
|
Gilead |
8.2 |
|
Biogen |
8.1 |
|
Regeneron |
6.0 |
|
Alexion |
4.7 |
|
Medivation |
4.3 |
|
Incyte |
3.1 |
|
Genmab |
3.1 |
|
Ophthotech |
2.8 |
|
|
----------- |
|
Total |
57.8 |
|
Portfolio Profitability |
% NAV |
|
Profitable |
67 |
|
Turning Profitable 2016 |
5 |
|
Unprofitable |
28 |
|
|
----------- |
|
Total |
100 |
|
Geographical Allocation |
% NAV |
|
US & Canada |
84 |
|
Europe & UK |
16 |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted Allocation |
% NAV |
|
Quoted |
88 |
|
Unquoted |
12 |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
29 MARCH 2016